

IMPORTANT INFORMATION

OneTest™ is NOT a definitive test for cancer.

Less than 1% of the general U.S. population is expected to be diagnosed with cancer each year.

About 10-20% of males and 20-25% of females taking OneTest™ are expected to receive high scores. You may receive a high score even if you don't have cancer.

Not every cancer can be detected with the cancer markers in OneTest™. Some people who actually have cancer may still receive a low score. Certain conditions, such as inflammatory diseases, are known to increase false positive rates with OneTest™.

OneTest™ requires a sample of blood from a vein (known as a venipuncture). Some people may experience discomfort during this procedure.

OneTest™ is not a genetic test. It does not identify information about inherited genetic risks of developing cancer.

OneTest™ looks at your markers associated with having cancer at the time of testing. It does not provide information regarding your risk of developing cancer in the future.

If the results reported by OneTest™ are high, your doctor may recommend that additional tests be performed by a medical specialist for further cancer evaluation.

If any tumor marker levels are higher than expected range, leading experts in the field of biomarker testing suggest getting tested again at more frequent intervals.

A definitive diagnosis of cancer is normally rendered only after a tissue biopsy and laboratory pathologic analyses are performed.

NEW Blood Test Helps Detect Multiple Cancers Early.



Powered by A.I. Technology



Provided in
Austria by:



Philipp.sabanas@gmail.com

drsabanas.com

(+43) 650-704-9442



Developed by:




An American Biotech Company

THE IMPORTANCE OF ONETEST™

There is a 40% risk of developing cancer in one's lifetime. Aging, not family history or lifestyle, is the major cause of most cancers.



OneTest™ helps in the detection of multiple cancers before symptoms occur, when treatments are more effective and less expensive. For most cancers, survival depends on early detection.



OneTest™ is the first test of its kind to combine the results of multiple cancer biomarker blood tests (from a single blood draw) and personal health data using an artificial intelligence algorithm to calculate a probability score for multiple types of cancer.

Armed with this important information, your physician may recommend further testing that reveals cancers before symptoms begin to appear, allowing for early intervention and higher survival rates.

OneTest™ was developed by American biotech company 2020 GeneSystems with data from a major hospital where thousands of people were screened over more than a decade with a panel of tumor marker tests.

THE POWER OF ONETEST™

Every year, millions of people outside the U.S. receive health check exams that include routine cancer-screening blood tests. With OneTest™, this type of early testing is now available in the United States.

OneTest™ helps detect these deadly cancers† with a single blood test:

- ▶ LUNG
- ▶ LIVER
- ▶ PANCREATIC
- ▶ PROSTATE
- ▶ KIDNEY
- ▶ OVARIAN
- ▶ AND MORE

Powered by A.I. Technology



† most deadly cancers, according to the American Cancer Society, 2018

SOME COMMON QUESTIONS

WHO SHOULD BE TESTED?

Cancer occurs more frequently in people above age 50 (based on published U.S. incidence data). In countries where broad cancer screening is common, screening typically begins at the age of 40.

WHAT INFORMATION DOES THE TEST PROVIDE?

OneTest™ results yield individual scores for multiple cancer tumor marker tests and an overall probability of having cancer now or within 1 year. Additional supporting information is provided that may suggest possible appropriate follow-up with a specialty care provider.

HOW OFTEN SHOULD I GET TESTED?

Numerous studies have found that annual testing can detect subtle changes in cancer marker scores that may successfully lead to early diagnoses of developing cancers.



FOR MORE INFORMATION VISIT
OneTestforCancer.com